Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease

Area of Science:

• Immunology
• Virology
• Biochemistry

Background:

• COVID-19, caused by SARS-CoV-2, has led to a global pandemic.
• Risk factors for severe COVID-19 include male sex, older age, and sedentary lifestyles.
• Prostaglandin E2 (PGE2) is implicated in inflammatory processes.

Purpose of the Study:

• To investigate the association between risk factors, SARS-CoV-2 infection, and PGE2 levels.
• To explore the role of PGE2 in COVID-19 pathogenesis and immune cell regulation.
• To evaluate potential interventions like exercise and Taxifolin.

Main Methods:

• Analysis of serum PGE2 levels in unaffected subjects and COVID-19 patients.
• In vitro studies using lung epithelial cells and precision cut lung slices (PCLS) infected with SARS-CoV-2.
• Assessment of Paired-Box-Protein-Pax-5 (PAX5) expression in response to PGE2 and SARS-CoV-2.
• Evaluation of the effect of Taxifolin on PGE2 production.

Main Results:

• Higher PGE2 levels were observed in individuals with COVID-19 risk factors and in COVID-19 patients, correlating with disease severity.
• SARS-CoV-2 infection upregulates cyclo-oxygenase (COX)-2 and downregulates 15-hydroxyprostaglandin-dehydrogenase, increasing PGE2 production.
• PGE2 suppressed PAX5 expression, crucial for B-cell immunity, in both healthy and infected conditions.
• Regular exercise lowered PGE2 and increased PAX5 expression in aged individuals.
• Taxifolin inhibited SARS-CoV-2-induced PGE2 production.

Conclusions:

• Elevated PGE2, driven by SARS-CoV-2, male sex, age, and inactivity, may impair early antiviral defense and adaptive immunity, leading to severe COVID-19.
• Regular exercise and Taxifolin treatment show potential in reducing COVID-19 severity by modulating PGE2 levels and enhancing immune responses.